{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:14:33Z","timestamp":1793873673603,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["18-CE17-0008"],"award-info":[{"award-number":["18-CE17-0008"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Individuals with high <jats:italic>Loa loa<\/jats:italic> microfilarial densities (MFD) risk serious adverse events (SAEs) following ivermectin treatment. A single dose of levamisole (LEV) induces a temporary, progressive MFD decrease. This double-blind, randomized, placebo-controlled trial evaluated the safety and efficacy of 3-day and 5-day LEV regimens for the treatment of loiasis in the Republic of the Congo. Participants were randomly assigned to receive placebo (PLA), LEV-3, or LEV-5. Safety was assessed by the occurrence of SAEs and the frequency and severity of AEs. Efficacy was measured by changes in <jats:italic>Loa loa<\/jats:italic> MFD. No SAEs were reported, and AE severity was comparable across treatment arms. On day 5, MFD reductions were greater in the LEV-3 and LEV-5 groups compared to PLA (\u2009\u22121.6%, 29.3%, and 51.4%, respectively; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). By day 7, a higher proportion of participants achieved \u226540% MFD reduction in the LEV-5 group (44.4%) compared to LEV-3 (34.6%) and PLA (8.3%) (<jats:italic>P<\/jats:italic>\u2009=\u20090.051). Post hoc contrasts confirmed significantly greater MFD reduction with LEV-5 versus LEV-3. These findings suggest that a 5-day LEV regimen is safe and moderately effective for reducing <jats:italic>L. loa<\/jats:italic> MFD and may represent a promising alternative for individualised management in loiasis-endemic areas, particularly where onchocerciasis is hypoendemic and coendemic with loiasis. Trial registration: NCT06252961.<\/jats:p>","DOI":"10.1038\/s41467-025-61479-6","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T16:56:37Z","timestamp":1751648197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of 3- and 5-day regimens of levamisole in loiasis: a randomized, placebo-controlled, double-blind clinical trial"],"prefix":"10.1038","volume":"16","author":[{"given":"C\u00e9dric B.","family":"Chesnais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlhand C.","family":"Hemilembolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachiratou A.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentin","family":"Toutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ericson","family":"Djeutassong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Nga-Elomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-0704","authenticated-orcid":false,"given":"Benjamin","family":"Cuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mas A.","family":"Ntsiba-N\u2019Goulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miveck","family":"Pakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien D. S.","family":"Pion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Missamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boussinesq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-5204","authenticated-orcid":false,"given":"J\u00e9r\u00e9my T.","family":"Campillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"61479_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001210","volume":"5","author":"HGM Zour\u00e9","year":"2011","unstructured":"Zour\u00e9, H. G. M. et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl. Trop. Dis. 5, e1210 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"61479_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","volume":"350","author":"J Gardon","year":"1997","unstructured":"Gardon, J. et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350, 18\u201322 (1997).","journal-title":"Lancet"},{"key":"61479_CR3","unstructured":"World Health Organization. Global report on neglected tropical diseases 2024. 2024. Available: https:\/\/www.who.int\/teams\/control-of-neglected-tropical-diseases\/global-report-on-neglected-tropical-diseases-2024."},{"key":"61479_CR4","doi-asserted-by":"publisher","first-page":"i40\u2013i48","DOI":"10.1093\/inthealth\/ihx054","volume":"10","author":"M Boussinesq","year":"2018","unstructured":"Boussinesq, M., Fobi, G. & Kuesel, A. C. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Health 10, i40\u2013i48 (2018).","journal-title":"Int Health"},{"key":"61479_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/infdis\/168.1.202","volume":"168","author":"AD Klion","year":"1993","unstructured":"Klion, A. D. et al. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J. Infect. Dis. 168, 202\u2013206 (1993).","journal-title":"J. Infect. Dis."},{"key":"61479_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1051\/parasite\/200209159","volume":"9","author":"J Kamgno","year":"2002","unstructured":"Kamgno, J. & Boussinesq, M. Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia. Parasite 9, 59\u201363 (2002).","journal-title":"Parasite"},{"key":"61479_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004492","volume":"10","author":"J Kamgno","year":"2016","unstructured":"Kamgno, J., Nguipdop-Djomo, P., Gounoue, R., T\u00e9jiokem, M. & Kuesel, A. C. Effect of two or six doses 800 mg of albendazole every two months on Loa loa microfilaraemia: a double blind, randomized, placebo-controlled trial. PLoS Negl. Trop. Dis. 10, 1\u201319 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"61479_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1179\/000349802125001933","volume":"96","author":"L Tsague-Dongmo","year":"2002","unstructured":"Tsague-Dongmo, L. et al. Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia. Ann. Trop. Med. Parasitol. 96, 707\u2013715 (2002).","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"61479_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4269\/ajtmh.2010.09-0573","volume":"82","author":"J Kamgno","year":"2010","unstructured":"Kamgno, J. et al. A Controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia. Am. J. Trop. Med. Hyg. 82, 379\u2013385 (2010).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"61479_CR10","first-page":"275","volume":"60","author":"J Kamgno","year":"2000","unstructured":"Kamgno, J., Gardon, J. & Boussinesq, M. Analysis of the prevention of post-ivermectin Loa loa encephalopathy by administration of initial low dose]. Med. Trop. 60, 275\u2013277 (2000).","journal-title":"Med. Trop."},{"key":"61479_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.trstmh.2007.03.018","volume":"101","author":"J Kamgno","year":"2007","unstructured":"Kamgno, J. et al. Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg\/kg) versus current standard dose (150 microg\/kg). T R. Soc. Trop. Med. H. 101, 777\u2013785 (2007).","journal-title":"T R. Soc. Trop. Med. H."},{"key":"61479_CR12","doi-asserted-by":"publisher","first-page":"ofae240","DOI":"10.1093\/ofid\/ofae240","volume":"11","author":"GS Wafeu","year":"2024","unstructured":"Wafeu, G. S. et al. Safety and short-term efficacy of a single dose of 2 mg moxidectin in Loa loa infected individuals: a double-blind, randomized ivermectin-controlled trial with ascending microfilarial densities. Open Forum Infect. Dis. 11, ofae240 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"61479_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cid\/ciab906","volume":"75","author":"JT Campillo","year":"2021","unstructured":"Campillo, J. T. et al. Safety and efficacy of levamisole in loiasis: a randomized, placebo-controlled, double-blind clinical trial. Clin. Infect. Dis. 75, 19\u201327 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"61479_CR14","doi-asserted-by":"publisher","first-page":"j4307","DOI":"10.1136\/bmj.j4307","volume":"358","author":"W Moser","year":"2017","unstructured":"Moser, W., Schindler, C. & Keiser, J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ 358, j4307 (2017).","journal-title":"BMJ"},{"key":"61479_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2165\/00003495-198020020-00005","volume":"20","author":"MJ Miller","year":"1980","unstructured":"Miller, M. J. Use of levamisole in parasitic infections. Drugs 20, 122\u2013130 (1980).","journal-title":"Drugs"},{"key":"61479_CR16","first-page":"113","volume":"77","author":"DR O\u2019Holohan","year":"1974","unstructured":"O\u2019Holohan, D. R. & Zaman, V. Treatment of Brugia malayi infection with levamisole. J. Trop. Med. Hyg. 77, 113\u2013115 (1974).","journal-title":"J. Trop. Med. Hyg."},{"key":"61479_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/0035-9203(73)90094-1","volume":"67","author":"V Zaman","year":"1973","unstructured":"Zaman, V. & Lal, M. Letter: Treatment of Wuchereria bancrofti with levamisole. Tran R. Soc. Trop. Med. Hyg. 67, 610 (1973).","journal-title":"Tran R. Soc. Trop. Med. Hyg."},{"key":"61479_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(81)90880-1","volume":"318","author":"AR Rivas-Alcala","year":"1981","unstructured":"Rivas-Alcala, A. R. et al. Chemotherapy of onchocerciasis: a controlled comparison of mebendazole, levamisole, and diethylcarbamazine. Lancet 318, 485\u2013490 (1981).","journal-title":"Lancet"},{"key":"61479_CR19","first-page":"571","volume":"9","author":"MV Narasimham","year":"1978","unstructured":"Narasimham, M. V., Roychowdhury, S. P., Das, M. & Rao, C. K. Levamisole and mebendazole in the treatment of bancroftian infection. Southeast Asian J. Trop. Med Public Health 9, 571\u2013575 (1978).","journal-title":"Southeast Asian J. Trop. Med Public Health"},{"key":"61479_CR20","first-page":"257","volume":"69","author":"M Merlin","year":"1976","unstructured":"Merlin, M., Carme, B., Kaeuffer, H. & Laigret, J. Activity of levamisole (Solaskil) in lymphatic filariasis caused by Wucheria bancrofti (variety pacifica]. Bull. Soc. Pathol. Exot. Filiales 69, 257\u2013265 (1976).","journal-title":"Bull. Soc. Pathol. Exot. Filiales"},{"key":"61479_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/00034983.1979.11687286","volume":"73","author":"JE McMahon","year":"1979","unstructured":"McMahon, J. E. Preliminary screening of antifilarial activity of levamisole and amodiaquine on Wuchereria bancrofti. Ann. Trop. Med Parasitol. 73, 465\u2013472 (1979).","journal-title":"Ann. Trop. Med Parasitol."},{"key":"61479_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/00034983.1982.11687567","volume":"76","author":"K Awadzi","year":"1982","unstructured":"Awadzi, K., Schulz-Key, H., Howells, R. E., Haddock, D. R. & Gilles, H. M. The chemotherapy of onchocerciasis VIII Levamisole and its combination with the benzimidazoles. Ann. Trop. Med. Parasitol. 76, 459\u2013473 (1982).","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"61479_CR23","first-page":"451","volume":"35","author":"J Moreau","year":"1975","unstructured":"Moreau, J., Radanielina, R. & Barbier, P. Activity of levamisole in Bancrofti filariasis. Med. Trop. 35, 451\u2013455 (1975).","journal-title":"Med. Trop."},{"key":"61479_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0035-9203(80)90081-4","volume":"74","author":"JW Mak","year":"1980","unstructured":"Mak, J. W. & Zaman, V. Drug trials with levamisole hydrochloride and diethylcarbamazine citrate in Bancroftian and Malayan filariasis. Trans. R. Soc. Trop. Med. Hyg. 74, 285\u2013291 (1980).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"61479_CR25","doi-asserted-by":"publisher","unstructured":"Vanden Bossche, H. Biochemical effects of tetramisole. in Comparative Biochemistry of Parasites 117\u2013125 https:\/\/doi.org\/10.1016\/B978-0-12-711050-9.50013-0 (Elsevier, 1972).","DOI":"10.1016\/B978-0-12-711050-9.50013-0"},{"key":"61479_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ajoms.2016.03.004","volume":"28","author":"ML Chandy","year":"2016","unstructured":"Chandy, M. L., Soman, C., Kumar, S. P., Kurup, S. & Jose, R. Understanding molecular mechanisms in multivariant actions of levamisole as an anti-helminthic, anti-inflammatory, antioxidant, anti-neoplastic and immunomodulatory drug. J. Oral. Maxillofac. Surg. Med. Pathol. 28, 354\u2013357 (2016).","journal-title":"J. Oral. Maxillofac. Surg. Med. Pathol."},{"key":"61479_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2307\/3280116","volume":"63","author":"RS Rew","year":"1977","unstructured":"Rew, R. S. & Saz, H. J. The carbohydrate metabolism of Brugia pahangi microfilariae. J. Parasitol. 63, 123\u2013129 (1977).","journal-title":"J. Parasitol."},{"key":"61479_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10158-015-0181-0","volume":"15","author":"E Mostafa","year":"2015","unstructured":"Mostafa, E. et al. Transient effects of levamisole on Brugia malayi microfilariae. Invert. Neurosci. 15, 5 (2015).","journal-title":"Invert. Neurosci."},{"key":"61479_CR29","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bcp.15037","volume":"88","author":"JT Campillo","year":"2021","unstructured":"Campillo, J. T. et al. Adverse reactions with levamisole vary according to its indications and misuse: a systematic pharmacovigilance study. Br. J. Clin. Pharm. 88, 1094\u20131106 (2021).","journal-title":"Br. J. Clin. Pharm."},{"key":"61479_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003495-198020020-00001","volume":"20","author":"G Renoux","year":"1980","unstructured":"Renoux, G. The general immunopharmacology of levamisole. Drugs 20, 89\u201399 (1980).","journal-title":"Drugs"},{"key":"61479_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF03189626","volume":"7","author":"M Luyckx","year":"1982","unstructured":"Luyckx, M. et al. Pharmacokinetics of levamisole in healthy subjects and cancer patients. Eur. J. Drug Metab. Pharmacokinet. 7, 247\u2013254 (1982).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"61479_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s002800050036","volume":"45","author":"P Gwilt","year":"2000","unstructured":"Gwilt, P., Tempero, M., Kremer, A., Connolly, M. & Ding, C. Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil. Cancer Chemother. Pharm. 45, 247\u2013251 (2000).","journal-title":"Cancer Chemother. Pharm."},{"key":"61479_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1708-8305.2012.00605.x","volume":"19","author":"M Boussinesq","year":"2012","unstructured":"Boussinesq, M. Loiasis: new epidemiologic insights and proposed treatment strategy. J. Travel Med. 19, 140\u2013143 (2012).","journal-title":"J. Travel Med."},{"key":"61479_CR34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1179\/000349804225021370","volume":"98","author":"K Awadzi","year":"2004","unstructured":"Awadzi, K. et al. The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus. Ann. Trop. Med. Parasitol. 98, 595\u2013614 (2004).","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"61479_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s13071-023-06056-w","volume":"16","author":"MC Hemilembolo","year":"2023","unstructured":"Hemilembolo, M. C. et al. Loa loa and Mansonella perstans microfilaremia in the department of L\u00e9koumou, Republic of Congo. Parasit. Vectors 16, 451 (2023).","journal-title":"Parasit. Vectors"},{"key":"61479_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13071-022-05612-0","volume":"16","author":"JT Campillo","year":"2023","unstructured":"Campillo, J. T. et al. Temporal variability of Loa loa microfilaraemia. Parasit. Vectors 16, 23 (2023).","journal-title":"Parasit. Vectors"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61479-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T16:56:39Z","timestamp":1751648199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61479-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61479"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61479-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6191"}}